Trials / Active Not Recruiting
Active Not RecruitingNCT05856448
A Study Evaluating the Effects of GLPG3667 Administered as Oral Treatment in Adult Participants With Active Systemic Lupus Erythematosus
A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered GLPG3667 in Adult Subjects With Active Systemic Lupus Erythematosus
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 186 (actual)
- Sponsor
- Galapagos NV · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
A study evaluating the efficacy, safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of GLPG3667 administered orally once daily for 48 weeks in approximately 180 adult participants with active Systemic Lupus Erythematosus (SLE).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GLPG3667 | Capsule |
| DRUG | Placebo | Capsule |
Timeline
- Start date
- 2023-06-28
- Primary completion
- 2025-10-08
- Completion
- 2026-03-01
- First posted
- 2023-05-12
- Last updated
- 2025-12-23
Locations
84 sites across 12 countries: United States, Argentina, Bulgaria, Chile, France, Georgia, Germany, Hungary, Peru, Poland, Puerto Rico, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05856448. Inclusion in this directory is not an endorsement.